Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings

BACKGROUND: A see on cardiovascular diseases and bladder cancer. The changes to the patterns of rosiglitazone and pioglitazone utilisation in Australia following the timing of these various health authority warnings such as the Australian Therapeutic Good Administration (TGA), European Medicines Age...

Descripción completa

Detalles Bibliográficos
Autores principales: Niyomnaitham, Suvimol, Page, Andrew, La Caze, Adam, Whitfield, Karen, Smith, Alesha J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994196/
https://www.ncbi.nlm.nih.gov/pubmed/24708579
http://dx.doi.org/10.1186/1472-6963-14-151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994196/
https://www.ncbi.nlm.nih.gov/pubmed/24708579
http://dx.doi.org/10.1186/1472-6963-14-151

Ejemplares similares